NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

Biktarvy is a first line treatment based on which regimen?

NNRTI-based
INSTI based
Fusion inhibitor
Post-attachment inhibitor

The correct answer is: INSTI based

Biktarvy is a first line treatment regimen based on INSTIs (integrase strand transfer inhibitors), a class of antiretroviral drugs that inhibit the enzyme integrase and prevent the integration of HIV genetic material into human DNA. This is considered the most effective and well-tolerated class of HIV medications, making it a first line treatment option. Option A, NNRTI (non-nucleoside reverse transcriptase inhibitor) based regimens are commonly used but are no longer recommended as first line treatments due to decreased effectiveness and potential for side effects. Option C, fusion inhibitors, work by blocking the fusion of HIV to human cells, but are not commonly used as a first line treatment due to limited availability and potential for side effects. Option D, post-attachment inhibitors, prevent HIV from binding to human cells and entering them, but are also not commonly used as first line treatments due to limited availability and potential for side effects. Therefore, B is the correct answer.